HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Pain Management · Neuromodulation Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Pain Management · Neuromodulation Therapeutic Area Assessment

172 signals · 8 insights · 774 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 68%

Evidence

954 items

Sources

4

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Pain Management · Neuromodulation integrates 172 signals, 8 executive insights, and 774 regulatory precedents from the Humanexa intelligence graph. 2 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJun 29, 2026

    FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc

    The FDA has approved the Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride submitted by Lannett Co Inc.

    View detail
  2. signalJun 25, 2026

    FDA Approval for Oxycodone Hydrochloride by Novel Labs

    The FDA has granted approval for ANDA204021, a supplemental application for Oxycodone Hydrochloride by Novel Labs.

    View detail
  3. signalJul 23, 2026

    FDA Approves Supplement for Buprenorphine Hydrochloride by Rubicon Research

    The FDA has approved a supplemental application for Buprenorphine Hydrochloride submitted by Rubicon Research.

    View detail
  4. signalJul 23, 2026

    FDA Grants Approval for Novitium's Tramadol Hydrochloride

    The FDA has granted approval for Novitium Pharma's ANDA219647 for Tramadol Hydrochloride.

    View detail
  5. regulatoryJul 23, 2026

    Other | Cancer Accelerated Approvals

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been granted for supportive care products and changes to dosing or formulation.

    View detail
  6. regulatoryJul 23, 2026

    Rare Disease Drug Approvals

    This page describes recent rare disease drug approvals that received CDER or FDA communication. This is not an exhaustive list of all rare disease drug approvals.

    View detail
  7. regulatoryJul 23, 2026

    Verified Clinical Benefit | Cancer Accelerated Approvals

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.

    View detail
  8. regulatoryJul 23, 2026

    CDER proposes to withdraw approval of TAVNEOS

    Why this matters: sets a approval precedent in the same sub-indication (pain) as Aurobindo Pharma; the same agency is already in play for this signal, so precedent weight is higher.

    View detail
  9. insightJun 30, 2026

    Omega Pharma Faces Market Risks from Napralief Recall Amid Competitive Pressures

    The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts. Regulatory context from MHRA (Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28) supports the near-term read. Assessment grounded in 2 ranked evidence items (2 high-relevance).

    View detail
  10. insightJun 28, 2026

    Sun Pharma's Levorphanol Tartrate Approval Disrupts Pain Management Landscape

    The FDA's approval of Sun Pharma's ANDA for Levorphanol Tartrate signifies a new entry into the pain management market, which could disrupt existing pricing structures and market shares. Competitors must be vigilant in adjusting their strategies to maintain their positions in this evolving landscape. Regulatory context from FDA (FDA AP — LEVORPHANOL TARTRATE (SUPPL)) supports the near-term read. Assessment grounded in 9 ranked evidence items (8 high-relevance).

    View detail
  11. insightJun 24, 2026

    Increased Competition in Opioid Pain Management Following Recent FDA Approvals

    The FDA's approval of Lannett's oxycodone hydrochloride presents a significant shift in the competitive landscape of the opioid market. This entry may lead to pricing pressures and market share erosion for existing players, requiring strategic responses to maintain competitive positioning. Regulatory context from FDA (FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 15 ranked evidence items (4 high-relevance).

    View detail
  12. insightJun 24, 2026

    Acertis Pharmaceuticals Gains Regulatory Momentum with Levorphanol Tartrate Application

    The FDA's acceptance of the supplemental application for Levorphanol Tartrate by Acertis Pharmaceuticals is significant as it positions Acertis to strengthen its foothold in the competitive opioid pain management market. This development necessitates close monitoring of market dynamics and potential responses from other manufacturers. Regulatory context from FDA (FDA AP — LEVORPHANOL TARTRATE (SUPPL)) supports the near-term read. Assessment grounded in 8 ranked evidence items (8 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 8 risk-calibrated assessments for portfolio review. 774 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 8 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Other | Cancer Accelerated Approvals

    66%

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been granted for supportive care products and changes to dosing or formulation.

    Source: FDA

    View evidence

  • Rare Disease Drug Approvals

    66%

    This page describes recent rare disease drug approvals that received CDER or FDA communication. This is not an exhaustive list of all rare disease drug approvals.

    Source: FDA

    View evidence

  • Verified Clinical Benefit | Cancer Accelerated Approvals

    84%

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.

    Source: FDA

    View evidence

  • CDER proposes to withdraw approval of TAVNEOS

    84%

    Why this matters: sets a approval precedent in the same sub-indication (pain) as Aurobindo Pharma; the same agency is already in play for this signal, so precedent weight is higher.

    Source: FDA

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    84%

    Why this matters: sets a approval precedent in the same sub-indication (pain) as Aurobindo Pharma; the same agency is already in play for this signal, so precedent weight is higher.

    Source: FDA

    View evidence

  • FDA AP — TRAMADOL HYDROCHLORIDE (ORIG)

    66%

    Application ANDA219647. Sponsor: NOVITIUM PHARMA. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: TRAMADOL HYDROCHLORIDE.

    Source: FDA

    View evidence

  • Omega Pharma Faces Market Risks from Napralief Recall Amid Competitive Pressures

    86%

    The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts. Regulatory context from MHRA (Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28) supports the near-term read. Assessment grounded in 2 ranked evidence items (2 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Sun Pharma's Levorphanol Tartrate Approval Disrupts Pain Management Landscape

    91%

    The FDA's approval of Sun Pharma's ANDA for Levorphanol Tartrate signifies a new entry into the pain management market, which could disrupt existing pricing structures and market shares. Competitors must be vigilant in adjusting their strategies to maintain their positions in this evolving landscape. Regulatory context from FDA (FDA AP — LEVORPHANOL TARTRATE (SUPPL)) supports the near-term read. Assessment grounded in 9 ranked evidence items (8 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Increased Competition in Opioid Pain Management Following Recent FDA Approvals

    43%

    The FDA's approval of Lannett's oxycodone hydrochloride presents a significant shift in the competitive landscape of the opioid market. This entry may lead to pricing pressures and market share erosion for existing players, requiring strategic responses to maintain competitive positioning. Regulatory context from FDA (FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 15 ranked evidence items (4 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Acertis Pharmaceuticals Gains Regulatory Momentum with Levorphanol Tartrate Application

    89%

    The FDA's acceptance of the supplemental application for Levorphanol Tartrate by Acertis Pharmaceuticals is significant as it positions Acertis to strengthen its foothold in the competitive opioid pain management market. This development necessitates close monitoring of market dynamics and potential responses from other manufacturers. Regulatory context from FDA (FDA AP — LEVORPHANOL TARTRATE (SUPPL)) supports the near-term read. Assessment grounded in 8 ranked evidence items (8 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Regulatory Scrutiny Intensifies Following Aspar Pharmaceuticals' Ibuprofen Recall

    51%

    The recall of Ibuprofen 200mg Tablets by Aspar Pharmaceuticals due to foil perforations raises concerns about product quality and safety. This situation could lead to increased regulatory scrutiny and impact market confidence, necessitating careful monitoring by pharma strategy teams. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 6 ranked evidence items (1 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Innovative Pediatric Pain Management: The Rise of Diclofenac Potassium Lollipop

    53%

    The development of a weight-adjusted diclofenac potassium lollipop represents a significant innovation in pediatric postoperative pain management. This formulation could enhance adherence to pain management protocols, potentially disrupting existing analgesic products in the market. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 10 ranked evidence items (2 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc

    Regulatory Approval

  • FDA Approval for Oxycodone Hydrochloride by Novel Labs

    Regulatory Approval

  • FDA Approves Supplement for Buprenorphine Hydrochloride by Rubicon Research

    Regulatory Approval

  • FDA Grants Approval for Novitium's Tramadol Hydrochloride

    Regulatory Approval

  • Trial Comparing Liposomal Bupivacaine and Dexamethasone for Postoperative Pain Control

    Trial Update

  • FDA Approval Letter for Morphine Sulfate by Fresenius Kabi USA

    Regulatory Approval

  • Study on Retrolaminar Block's Impact on Opioid Use in Spine Surgery

    Trial Update

  • Trial Evaluates Superficial Cervical Block to Reduce Opioid Use in Cervical Discectomy

    Trial Update

Insights

  • Omega Pharma Faces Market Risks from Napralief Recall Amid Competitive Pressures

    Pain Management · OTC

  • Sun Pharma's Levorphanol Tartrate Approval Disrupts Pain Management Landscape

    Pain Management · Opioid

  • Increased Competition in Opioid Pain Management Following Recent FDA Approvals

    Pain Management · Opioid

  • Acertis Pharmaceuticals Gains Regulatory Momentum with Levorphanol Tartrate Application

    Pain Management · Opioid

  • Regulatory Scrutiny Intensifies Following Aspar Pharmaceuticals' Ibuprofen Recall

    Pain Management · NSAID

  • Innovative Pediatric Pain Management: The Rise of Diclofenac Potassium Lollipop

    Pain Management · Pediatric

  • Regulatory Approvals Enhance Competitive Landscape in Pain Management Market

    Pain Management · Analgesics

  • Emerging Clinical Trials in Pain Management: Strategic Implications for Market Dynamics

    Pain Management · Chronic Low Back Pain

Companies

  • Hikma

    30 signals

  • Teva

    25 signals

  • Aurobindo Pharma

    28 signals

  • Sun Pharma

    24 signals

  • Novitium Pharma

    16 signals

  • Sciegen Pharmaceuticals

    15 signals

  • Strides Pharma

    12 signals

  • Macleods Pharmaceuticals

    10 signals

Assets

  • Levorphanol Tartrate
  • Levorphanol Tartrate
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.